Skip to main content
Log in

Leadless Pacemaker Technologies: Patient Selection, Approach, and Outcomes

  • Arrhythmias (J. Bunch, Section Editor)
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Leadless cardiac pacemakers have recently entered clinical use for patients requiring single ventricular chamber pacing only. Two leadless systems have been utilized, the Nanostim leadless cardiac pacemaker and the Micra transcatheter pacing system. While currently limited to only a minority of pacemaker eligible patients, technical hurdles are expected to be overcome which will allow this technology to reach a much broader population. This review discusses the patient population for which these devices are indicated, the approach to device implantation and retrieval, and ongoing data on their long-term use.

Recent Findings

Two major non-randomized clinical trials investigating the Nanostim and Micra leadless pacemaker systems were published in the New England Journal of Medicine in 2015 and 2016, respectively, with implant success rates of the active and passive fixation devices of 95.8 and 99.2%, respectively. The Nanostim and Micra demonstrated efficacy and safety, with major complication rates of 6.7 and 4% at 6 months, respectively, comparing favorably to historical transvenous pacemaker controls. Ongoing real-world registry data from Micra shows similar results, whereas Nanostim implantations have been halted due to an unexpected battery malfunction alert in late 2016. More data on device retrieval has become available, along with other strategies for end-of-life management.

Summary

Leadless pacemakers have emerged in clinical use based on their clinical outcomes and safety profile. These devices are expected to further revolutionize the field of cardiac pacing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Kirkfeldt RE, Johansen JB, Nohr EA, Jorgensen OD, Nielsen JC. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J. 2014;35:1186–94.

    Article  PubMed  Google Scholar 

  2. Udo EO, Zuithoff NPA, van Hemel NM, de Cock CC, Hendriks T, Doevendans PA, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Hearth Rhythm. 2012;9:728–35.

    Article  Google Scholar 

  3. • Cantillon DJ, Exner DV, Badie N, Davis K, Gu NY, Nabutovsky Y, et al. Complications and health care costs associated with transvenous cardiac pacemakers in a nationwide assessment. JACC Clin Electrophysiol Elsevier. 2017;3:1296–305. This study provides real-world claims data suggesting that transvenous pacemaker complicatons are more common than previously reported, affecting nearly 1 in 6 patients by 3 years and contributing to incremental US health care cost.

    Article  Google Scholar 

  4. •• Reddy VY, Exner DV, Cantillon DJ, Doshi R, Bunch TJ, Tomassoni GF, et al. Percutaneous implantation of an entirely intracardiac leadless pacemaker. N Engl J Med. 2015;373:1125–35. This is the first major non-randomized clinical trial investigating the Nanostim leadless pacemaker, reporting 6-month implant success rates of 95.8% and major complication rates of 6.7%.

    Article  CAS  PubMed  Google Scholar 

  5. •• Reynolds D, Duray GZ, Omar R, Soejima K, Neuzil P, Zhang S, et al. A leadless intracardiac transcatheter pacing system. N Engl J Med Mass Med Soc. 2016;374:533–41. This is the first major non-randomized clinical trial investigating the Micra leadless pacemaker, reporting 6-month implant success rates of 99.2% and major complication rates of 4%.

    Article  CAS  Google Scholar 

  6. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR, Ho RT, et al. Trends in permanent pacemaker implantation in the United States from 1993 to 2009. J Am Coll Cardiol. 2012;60:1540–5.

    Article  PubMed  Google Scholar 

  7. Reddy VY, Miller MA, Neuzil P, Søgaard P, Butter C, Seifert M, et al. Cardiac resynchronization therapy with wireless left ventricular endocardial pacing. J Am Coll Cardiol. 2017;69:2119–29.

    Article  PubMed  Google Scholar 

  8. Tjong FVY, Brouwer TF, Kooiman KM, Smeding L, Koop B, Soltis B, et al. Communicating antitachycardia pacing-enabled leadless pacemaker and subcutaneous implantable defibrillator. J Am Coll Cardiol. 2016;67:1865–6.

    Article  PubMed  Google Scholar 

  9. Auricchio A, Delnoy P-P, Butter C, Brachmann J, Van Erven L, Spitzer S, et al. Feasibility, safety, and short-term outcome of leadless ultrasound-based endocardial left ventricular resynchronization in heart failure patients: results of the Wireless Stimulation Endocardially for CRT (WiSE-CRT) study. Europace. 2014;16:681–8.

    Article  PubMed  Google Scholar 

  10. Tanaka-Esposito C, Cantillon D. Use of the leadless pacemaker to provide empiric pacing support for a young patient with prior ablation of a mid-septal accessory pathway resulting in damage to the compact AV node. J Innov Card Rhythm Manag. 2017;8:2717–23.

    Article  Google Scholar 

  11. Sanhoury M, Fassini G, Tundo F, Moltrasio M, Ribatti V, Lumia G, et al. Rescue leadless pacemaker implantation in a pacemaker-dependent patient with congenital heart disease and no alternative routes for pacing. J Atr Fibrillation Cardio Front, LLC. 2017;9:1542.

    Article  Google Scholar 

  12. De Regibus V, Moran D, Chierchia GB, Brugada P, de Asmundis C. Leadless pacing in a young patient with cardioinhibitory vasovagal syncope. Indian Pacing Electrophysiol J Elsevier. 2017. https://doi.org/10.1016/j.ipej.2017.12.003

  13. Reddy VY, Miller MA, Knops RE, Neuzil P, Defaye P, Jung W, et al. Retrieval of the leadless cardiac pacemaker. Circ Arrhythmia Electrophysiol. 2016;9:e004626.

    Article  Google Scholar 

  14. Wilkoff BL, Kennergren C, Love CJ, Kutalek SP, Epstein LM, Carrillo R. Bridge to surgery: best practice protocol derived from early clinical experience with the bridge occlusion balloon. Federated agreement from the eleventh annual lead management symposium. Hearth Rhythm Elsevier. 2017;14:1574–8.

    Article  Google Scholar 

  15. Olgun H, Karagoz T, Celiker A, Ceviz N. Patient- and lead-related factors affecting lead fracture in children with transvenous permanent pacemaker. Eur Oxf Univ Press. 2008;10:844–7.

    Google Scholar 

  16. Helguera ME, Maloney JD, Pinski SL, Woscoboinik JR, Wilkoff BL, Castle LW. Long-term performance of endocardial pacing leads. Pacing Clin Electrophysiol. 1994;17:56–64.

    Article  CAS  PubMed  Google Scholar 

  17. Lloyd MS, El-Chami MF, Nilsson KR, Cantillon DJ. Hands-On: transcatheter/leadless pacing. Hearth Rhythm. 2017. https://doi.org/10.1016/j.hrthm.2017.12.004

  18. Grubman E, Ritter P, Ellis CR, Giocondo M, Augostini R, Neuzil P, et al. To retrieve, or not to retrieve: system revisions with the Micra transcatheter pacemaker. Hearth Rhythm. 2017;14:1801–6.

    Article  Google Scholar 

  19. Chen K, Zheng X, Dai Y, Wang H, Tang Y, Lan T, et al. Multiple leadless pacemakers implanted in the right ventricle of swine. Europace. 2016;18:1748–52.

    Article  PubMed  Google Scholar 

  20. Roberts PR, Clementy N, Al Samadi F, Garweg C, Martinez-Sande JL, Iacopino S, et al. A leadless pacemaker in the real-world setting: the Micra Transcatheter Pacing System Post-Approval Registry. Hearth Rhythm. 2017;14(9):1375–9.

    Article  Google Scholar 

  21. Lakkireddy D, Knops R, Atwater B, Neuzil P, Ip J, Gonzalez E, et al. A worldwide experience of the management of battery failures and chronic device retrieval of the Nanostim leadless pacemaker. Hearth Rhythm. 2017;14:1756–63.

    Article  Google Scholar 

  22. Reddy VY, Knops RE, Sperzel J, Miller MA, Petru J, Simon J, et al. Permanent leadless cardiac pacing: results of the LEADLESS trial. Circulation. 2014;129:1466–71.

    Article  PubMed  Google Scholar 

  23. Piccini JP, Stromberg K, Jackson KP, Laager V, Duray GZ, El-Chami M, et al. Long-term outcomes in leadless Micra transcatheter pacemakers with elevated thresholds at implantation: results from the Micra Transcatheter Pacing System Global Clinical Trial. Hearth Rhythm. 2017;14:685–91.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniel J. Cantillon.

Ethics declarations

Conflict of Interest

Dr. Koene declared no conflict of interest. Dr. Cantillon reported consulting for Boston Scientific Corporation and Abbott Laboratories; membership on advisory committees for Boston Scientific Corporation and Abbott Laboratories; and teaching/speaking for Boston Scientific Corporation.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the author.

Additional information

This article is part of the Topical Collection on Arrhythmias

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koene, R.J., Cantillon, D.J. Leadless Pacemaker Technologies: Patient Selection, Approach, and Outcomes. Curr Cardiovasc Risk Rep 12, 11 (2018). https://doi.org/10.1007/s12170-018-0575-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s12170-018-0575-8

Keywords

Navigation